Genentech's Phase III STARGLO study shows Columvi extended survival in relapsed/refractory DLBCL patients, outperforming R-GemOx.
Genentech's Phase III STARGLO study shows Columvi significantly extends survival in relapsed or refractory diffuse large B-cell lymphoma patients. The study found that Columvi in combination with gemcitabine and oxaliplatin (GemOx) significantly extended survival compared to Rituxan (rituximab) in combination with GemOx (R-GemOx) for patients who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, or have received two or more prior lines of therapy.
June 15, 2024
6 Articles